公开(公告)号：US20170233339A1

公开(公告)日：2017-08-17

申请号：US15518782

申请日：2015-10-22

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Yoshihiro BANNO ,  Masahiro KAMAURA ,  Takahiko TANIGUCHI ,  Kazuaki TAKAMI ,  Koichiro FUKUDA ,  Shigekazu SASAKI

IPC: C07D207/08

CPC classification number: C07D207/08 ,  A61K31/40 ,  A61K31/401 ,  C12N15/09

Abstract: Provided is a heterocyclic compound having a superior RBP4-lowering action and useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4. A compound represented by the formula (I): wherein each symbol is as defined in the Description, or a salt thereof has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.

公开(公告)号：US20160264536A1

公开(公告)日：2016-09-15

申请号：US15031505

申请日：2014-10-22

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masaki SETO ,  Yoshihiro BANNO ,  Toshihiro IMAEDA ,  Yuichi KAJITA ,  Tomoko ASHIZAWA ,  Masanori KAWASAKI ,  Shinji NAKAMURA ,  Satoshi MIKAMI ,  Izumi NOMURA ,  Takahiko TANIGUCHI ,  Shogo MARUI

IPC: C07D277/56 ,  C07D403/12 ,  C07D239/28 ,  C07D403/04 ,  C07D239/47 ,  C07D239/36 ,  C07D239/52 ,  C07D241/24 ,  C07D498/08 ,  C07D413/04 ,  C07D405/04 ,  C07D401/04 ,  C07D417/04 ,  C07D409/04 ,  C07D401/12 ,  C07D239/42

CPC classification number: C07D277/56 ,  C07D239/28 ,  C07D239/36 ,  C07D239/42 ,  C07D239/47 ,  C07D239/48 ,  C07D239/52 ,  C07D239/54 ,  C07D239/56 ,  C07D241/24 ,  C07D241/26 ,  C07D277/20 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D403/04 ,  C07D403/12 ,  C07D405/04 ,  C07D409/04 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14 ,  C07D498/04 ,  C07D498/08

Abstract: The problem of the present invention is to provide a compound having a PDE2A inhibitory action, and useful as a prophylactic or therapeutic drug for schizophrenia, Alzheimer's disease and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

Abstract translation: 其中每个符号如说明书中所述或其盐。

公开(公告)号：US20220411369A1

公开(公告)日：2022-12-29

申请号：US17777943

申请日：2020-11-18

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Atsuko NISHIGUCHI ,  Osamu YABE ,  Yoshihiro BANNO

IPC: C07D207/14

Abstract: The present invention provides a production method suitable for industrial production of (2S,3S)-3-amino-2-(3-bromo-2-fluorobenzyl)pyrrolidine having a protecting group at the 1-position.
The present invention is a method for producing N-[(4-methylphenyl)sulfonyl]-L-phenylalanine salt of (2S,3S)-3-amino-2-(3-bromo-2-fluorobenzyl)pyrrolidine having a protecting group at the 1-position, which comprises Step 2: a step of subjecting 2-(3-bromo-2-fluorobenzyl)-3-(methoxyimino)pyrrolidine having a protecting group at the 1-position to a reduction reaction; and Step 3: a step of subjecting the product obtained in Step 2 to optical resolution using salt formation with N-[(4-methylphenyl)sulfonyl]-L-phenylalanine.

公开(公告)号：US20210269420A1

公开(公告)日：2021-09-02

申请号：US17256330

申请日：2019-06-27

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Tatsuhiko FUJIMOTO ,  Koichiro FUKUDA ,  Hiromichi SUGIMOTO ,  Kentaro RIKIMARU ,  Yoshihiro BANNO ,  Takahiro MATSUMOTO ,  Norihito TOKUNAGA ,  Yoshihide TOMATA ,  Yuji ISHICHI ,  Shogo MARUI ,  Tsuneo ODA ,  Tohru MIYAZAKI ,  Yasutaka HOASHI ,  Yasushi HATTORI ,  Yuichi KAJITA ,  Yuhei MIYANOHANA ,  Tatsuki KOIKE

IPC: C07D401/14 ,  C07D405/14 ,  C07D211/56

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US20180237404A1

公开(公告)日：2018-08-23

申请号：US15517227

申请日：2015-10-22

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Yoshihiro BANNO ,  Masahiro KAMAURA ,  Kazuaki TAKAMI ,  Koichiro FUKUDA ,  Shigekazu SASAKI

IPC: C07D263/46 ,  C07D213/70 ,  C07D231/12 ,  A61P27/02

CPC classification number: C07D263/46 ,  A61K31/415 ,  A61K31/421 ,  A61K31/4418 ,  A61K31/505 ,  A61P27/02 ,  C07D213/65 ,  C07D213/70 ,  C07D231/12 ,  C07D231/22 ,  C07D239/34 ,  C07D263/38 ,  C07K14/47 ,  C12N15/09

Abstract: Provided is a heterocyclic compound having a superior RBP4-lowering action and useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4. A compound represented by the formula (I): wherein each symbol is as defined in the Description, or a salt thereof has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.

公开(公告)号：US20170349605A1

公开(公告)日：2017-12-07

申请号：US15539607

申请日：2015-12-24

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Minoru SASAKI ,  Fumiaki KIKUCHI ,  Zenichi IKEDA ,  Keiko KAKEGAWA ,  Yoichi NISHIKAWA ,  Shigekazu SASAKI ,  Koichiro FUKUDA ,  Kazuaki TAKAMI ,  Yoshihiro BANNO ,  Masahiro KAMAURA

IPC: C07D495/04 ,  C07D491/044 ,  C07D413/06 ,  C07D323/00 ,  C07D313/00 ,  C07D321/12 ,  C07D321/00 ,  C07D313/20 ,  C07D493/04 ,  C07D405/06

CPC classification number: C07D495/04 ,  A61K31/365 ,  A61K31/381 ,  A61K31/4025 ,  A61K31/422 ,  A61K31/662 ,  C07D313/00 ,  C07D313/20 ,  C07D321/00 ,  C07D321/12 ,  C07D323/00 ,  C07D405/06 ,  C07D409/12 ,  C07D413/06 ,  C07D491/044 ,  C07D493/04 ,  C07F9/655

Abstract: The present invention relates to a condensed heterocyclic compound that has an enteropeptidase inhibitory effect and is useful in the treatment or prevention of obesity, diabetes mellitus, or the like, and a medicament containing the same. Specifically, the present invention relates to a compound represented by the following formula (I) or a salt thereof, and a medicament containing the same [in the formula, each symbol is as defined in the specification].